MA49285A - Composés hétéroaryle bicycliques fusionnés en 6-6 et leur utilisation comme inhibiteurs de lats - Google Patents

Composés hétéroaryle bicycliques fusionnés en 6-6 et leur utilisation comme inhibiteurs de lats

Info

Publication number
MA49285A
MA49285A MA049285A MA49285A MA49285A MA 49285 A MA49285 A MA 49285A MA 049285 A MA049285 A MA 049285A MA 49285 A MA49285 A MA 49285A MA 49285 A MA49285 A MA 49285A
Authority
MA
Morocco
Prior art keywords
heteraryl
lat
inhibitors
bicyclic compounds
compounds fused
Prior art date
Application number
MA049285A
Other languages
English (en)
Inventor
Dirk Behnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA49285A publication Critical patent/MA49285A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/27—Lung cells, respiratory tract cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049285A 2017-04-28 2018-04-26 Composés hétéroaryle bicycliques fusionnés en 6-6 et leur utilisation comme inhibiteurs de lats MA49285A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762491526P 2017-04-28 2017-04-28
US201762491475P 2017-04-28 2017-04-28
US201762491484P 2017-04-28 2017-04-28
US201762491573P 2017-04-28 2017-04-28
US201862650232P 2018-03-29 2018-03-29

Publications (1)

Publication Number Publication Date
MA49285A true MA49285A (fr) 2020-03-04

Family

ID=62148436

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049285A MA49285A (fr) 2017-04-28 2018-04-26 Composés hétéroaryle bicycliques fusionnés en 6-6 et leur utilisation comme inhibiteurs de lats

Country Status (25)

Country Link
US (2) US11458138B2 (fr)
EP (1) EP3615537B1 (fr)
JP (2) JP7247102B2 (fr)
KR (1) KR20190142776A (fr)
CN (3) CN114703144A (fr)
AU (2) AU2018260495B2 (fr)
BR (1) BR112019022512A2 (fr)
CA (1) CA3056906A1 (fr)
CL (1) CL2019003049A1 (fr)
CO (1) CO2019011873A2 (fr)
CR (1) CR20190483A (fr)
CU (2) CU20200080A7 (fr)
DO (1) DOP2019000273A (fr)
EC (1) ECSP19076732A (fr)
ES (1) ES2983611T3 (fr)
IL (2) IL269293B (fr)
JO (1) JOP20190257A1 (fr)
MA (1) MA49285A (fr)
MX (1) MX2019012756A (fr)
PE (1) PE20200292A1 (fr)
PH (1) PH12019502436A1 (fr)
SG (1) SG11201908615RA (fr)
TW (1) TW201843140A (fr)
UY (1) UY37703A (fr)
WO (1) WO2018198077A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
KR20190130608A (ko) 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
EP3804707A4 (fr) 2018-06-08 2022-03-16 Nissan Chemical Corporation Inhibiteur de kinase
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
CA3115998A1 (fr) * 2018-10-16 2020-04-23 The Schepens Eye Research Institute, Inc. Bioadhesif pour reparation de tissus mous
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
EP3896158A4 (fr) * 2018-12-11 2022-11-02 Kyoto University Procédé pour induire une délétion dans de l'adn génomique
TW202043199A (zh) 2019-01-30 2020-12-01 日商日產化學股份有限公司 醯肼化合物及激酶抑制劑
CN112707905B (zh) * 2019-10-25 2024-07-02 武汉誉祥医药科技有限公司 一种三并杂环化合物及其制备方法和用途
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
WO2021108483A1 (fr) * 2019-11-27 2021-06-03 Genentech, Inc. Composés thérapeutiques
US12617785B2 (en) * 2020-02-05 2026-05-05 The Rockefeller University Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
PE20230845A1 (es) * 2020-04-28 2023-05-23 Global Blood Therapeutics Inc Pirimidinas cicloalquiladas como inhibidores de la ferroportina
CN112305126A (zh) * 2020-11-02 2021-02-02 宁夏贝利特生物科技有限公司 一种硝酸胍含量的测定方法
AU2022284188A1 (en) * 2021-06-04 2023-11-30 Genentech, Inc. 2, 8-diazaspiro [4.5] decane compounds
CN117795330A (zh) * 2021-08-23 2024-03-29 Emd密理博公司 用于光聚合电泳凝胶的系统和方法
CN115974868B (zh) * 2022-11-07 2024-04-12 安徽理工大学 一种尿嘧啶衍生物的合成方法及其抗肺纤维化方面的潜在应用
WO2024211621A1 (fr) * 2023-04-04 2024-10-10 Children's Hospital Los Angeles Inhibiteur de kinase lats pour traitement de la dégénérescence rétinienne
CN119462609B (zh) * 2024-10-25 2025-12-26 烟台皓元生物医药科技有限公司 一种lats抑制剂vt02956的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (fr) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
EP1871377A1 (fr) 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd Derives de 2 , 4-diamino-pyridopyrimidine et leur utilisation comme inhibiteurs mtor
WO2008122614A1 (fr) 2007-04-06 2008-10-16 Novartis Ag Derives de 2,6-naphthyridine utilises en tant que modulateurs des proteines kinases
EP2318377B1 (fr) 2008-07-31 2013-08-21 Genentech, Inc. Composés de pyrimidine, compositions et procédés d'utilisation
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
US9347041B2 (en) * 2011-07-15 2016-05-24 Osaka University Method for preparing corneal endothelial cell
CA2845191A1 (fr) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Composes de type pyrazol-4-yl-heterocyclyl-carboxamide et leurs methodes d'utilisation
EA030253B1 (ru) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Азахиназолиновые ингибиторы атипичной протеинкиназы c
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
TWI675836B (zh) 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
EP3197557A1 (fr) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats et cancer du sein
TW201718536A (zh) 2015-08-03 2017-06-01 必治妥美雅史谷比公司 可作為ＴＮＦα調節劑之雜環化合物
US20200216906A1 (en) 2015-08-25 2020-07-09 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Also Published As

Publication number Publication date
CA3056906A1 (fr) 2018-11-01
RU2019138304A3 (fr) 2021-07-13
JP2022188056A (ja) 2022-12-20
WO2018198077A3 (fr) 2019-02-14
DOP2019000273A (es) 2019-12-15
EP3615537A2 (fr) 2020-03-04
CN114621222B (zh) 2024-12-17
SG11201908615RA (en) 2019-11-28
WO2018198077A2 (fr) 2018-11-01
CN110573511B (zh) 2023-04-25
US20180344738A1 (en) 2018-12-06
ES2983611T3 (es) 2024-10-23
CL2019003049A1 (es) 2020-02-07
ECSP19076732A (es) 2019-10-31
JOP20190257A1 (ar) 2019-10-28
CR20190483A (es) 2019-11-20
CU20190086A7 (es) 2020-11-30
AU2021286281A1 (en) 2022-01-06
CO2019011873A2 (es) 2020-01-17
EP3615537B1 (fr) 2024-03-06
KR20190142776A (ko) 2019-12-27
JP2020517698A (ja) 2020-06-18
CN110573511A (zh) 2019-12-13
CN114703144A (zh) 2022-07-05
JP7247102B2 (ja) 2023-03-28
UY37703A (es) 2018-11-30
MX2019012756A (es) 2019-12-16
AU2018260495B2 (en) 2021-09-16
TW201843140A (zh) 2018-12-16
PH12019502436A1 (en) 2020-07-20
PE20200292A1 (es) 2020-02-05
IL292857A (en) 2022-07-01
CU20200080A7 (es) 2021-05-12
US20230190751A1 (en) 2023-06-22
IL269293B (en) 2022-06-01
IL269293A (en) 2019-11-28
CN114621222A (zh) 2022-06-14
RU2019138304A (ru) 2021-05-28
AU2018260495A1 (en) 2019-10-17
BR112019022512A2 (pt) 2020-06-16
US11458138B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
IL269293B (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
EP4034094A4 (fr) Inhibiteurs de phosphodiestérase et leur utilisation
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
MA51224A (fr) Composés de sulfonamide et leur utilisation
EP3681499A4 (fr) Composés utilisés comme inhibiteurs de ras et leur utilisation
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA39838A (fr) Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
EP3732239A4 (fr) Composition de polyéthylène
EP3271436A4 (fr) Composition adhésive thermofusible et son utilisation
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
EP3250035A4 (fr) Composés et leur utilisation en tant qu'inhibiteurs de bace1
IL247194A0 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA45113A (fr) Composés mic-1 et leur utilisation
EP3553146A4 (fr) Composition adhésive et son utilisation
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
EP3538619A4 (fr) Composition adhésive thermofusible réactive et utilisation associée
EP3504335A4 (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
EP3492526A4 (fr) Composition de résine et utilisation correspondante
EP3212290A4 (fr) Polypeptides de fusion de serpine et leurs procédés d'utilisation
EP3313865A4 (fr) Composés peptidiques synthétiques et procédés d'utilisation
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
IL278701A (en) Heterofused pyridones and their use as IDH inhibitors